Unique metastases of ALK mutated lung cancer activated to the adnexa of the uterus.
Unique metastases of ALK mutated lung cancer activated to the adnexa of the uterus.
复制标题
DOI：
10.5430/crcp.v1n2p151
复制
发表时间：
2014-09
期刊：
影响因子：
--
通讯作者：
Salgia R
中科院分区：
文献类型：
--
作者：
West AH;Yamada SD;MacMahon H;Acharya SS;Ali SM;He J;Lukas RV;Miller VA;Salgia R
间变性淋巴瘤激酶(ALK)融合阳性非小细胞肺癌(NSCLC)是肺癌中一种较新的分子亚型。碱性磷酸酶靶向治疗，如Crizotinib，可增加该患者群体的生存收益。然而，需要进一步了解疾病亚型，包括转移模式和治疗耐药途径。我们描述一位50岁女性，诊断为IV期NSCLC，T2N3M1b，ALK融合阳性疾病。尽管她最初的转移部位包括肝脏和骨骼，但她的故事值得注意的是她的附件转移灶对克里佐替尼耐药生长。这份报告引起了人们对ALK阳性患者独特的转移机制的关注。
Anaplastic lymphoma kinase (ALK) fusion positive non-small cell lung cancer (NSCLC) is a relatively novel molecular subtype in lung cancer. ALK targeted therapies such as crizotinib increase survival benefit in this patient population. However, further understanding of the disease subtype including patterns of metastasis and pathways of treatment resistance are needed. We describe a 50 year-old-woman diagnosed with stage IV NSCLC, T2N3M1b, ALK fusion positive disease. Although her initial sites of metastasis included the liver and bone, her story is notable for crizotinib resistant growth of a metastatic lesion to her adnexa. This report brings to attention unique mechanisms of metastasis in ALK positive patients.